+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neurosigma Inc - Product Pipeline Analysis, 2021 Update

  • ID: 5367388
  • Company Profile
  • June 2021
  • 43 pages
  • GlobalData
  • NeuroSigma Inc

FEATURED COMPANIES

  • CJPS Medical Systems, LLC
  • InnovaQuartz LLC
  • NeuroMEDx
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Neurosigma Inc (Neurosigma) is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. It offers Monarch eTNS System for treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD). The company offers treatments for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stress disorders. It also conducts preclinical research and development, and phase clinical trials. The company trigeminal nerve stimulation has been investigated as a therapy for epilepsy, depression, attention deficity hyperactivity disorder, and post-traumatic stress disorder, Lennox-Gastaut syndrome and traumatic brain injuries, among others. NeuroSigma is headquartered in Los Angeles, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and helps to create effective counter strategies to gain a competitive advantage.

Scope
  • The report reviews the detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Neurosigma Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides a detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • CJPS Medical Systems, LLC
  • InnovaQuartz LLC
  • NeuroMEDx
Neurosigma Inc Company Overview
  • Neurosigma Inc Company Snapshot
  • Neurosigma Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Neurosigma Inc - Pipeline Analysis Overview
  • Neurosigma Inc - Key Facts
  • Neurosigma Inc - Major Products and Services
  • Neurosigma Inc Pipeline Products by Development Stage
  • Neurosigma Inc Ongoing Clinical Trials by Trial Status
Neurosigma Inc Pipeline Products Overview
  • Deep Brain Stimulation System - Cachexia
  • Deep Brain Stimulation System - Cachexia Product Overview
  • Deep Brain Stimulation System - Obesity
  • Deep Brain Stimulation System - Obesity Product Overview
  • DELTA Stent
  • DELTA Stent Product Overview
  • Micropatterned TFN Stent
  • Micropatterned TFN Stent Product Overview
  • Monarch eTNS System - ADHD
  • Monarch eTNS System - ADHD Product Overview
  • Monarch eTNS System - Depression
  • Monarch eTNS System - Depression Product Overview
  • Monarch eTNS System - Depression Clinical Trial
  • Monarch eTNS System - Epilepsy
  • Monarch eTNS System - Epilepsy Product Overview
  • Monarch eTNS System - Epilepsy Clinical Trial
  • Monarch eTNS System - Lennox-Gastaut Syndrome
  • Monarch eTNS System - Lennox-Gastaut Syndrome Product Overview
  • Monarch eTNS System - Post-Traumatic Stress Disorder
  • Monarch eTNS System - Post-Traumatic Stress Disorder Product Overview
  • Monarch eTNS System - Traumatic Brain Injury
  • Monarch eTNS System - Traumatic Brain Injury Product Overview
  • Next-Generation eTNS System
  • Next-Generation eTNS System Product Overview
  • sTNS System - Epilepsy
  • sTNS System - Epilepsy Product Overview
  • Thin Film Nitinol Flow Diverting Stent
  • Thin Film Nitinol Flow Diverting Stent Product Overview
Neurosigma Inc - Key Competitors

Neurosigma Inc - Key Employees

Neurosigma Inc - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Neurosigma Inc, Recent Developments
  • Oct 08, 2019: NeuroSigma announces partnership with Quick Care Pharmacy for sales and distribution of the Monarch eTNS System in the US
  • Jun 27, 2019: NeuroSigma announces presentation of clinical trial data showing increased brain activity and improved cognition in children with ADHD Treated with eTNS
  • May 01, 2019: CCHR condemns FDA's approval of Electricity-Zapping for 'ADHD' kids
  • Apr 23, 2019: NeuroSigma announces FDA clearance of Monarch eTNS System as first non-drug treatment for pediatric ADHD
  • Apr 23, 2019: FDA clears NeuroSigma’s Monarch device to treat ADHD
  • Oct 30, 2017: UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma's Non-Invasive eTNS System for Treatment of Pediatric ADHD
  • Jan 28, 2016: Electric patch holds promise for treating PTSD
  • Dec 10, 2015: Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting
  • Nov 16, 2015: NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD
  • May 04, 2015: NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting
Appendix
  • Methodology
  • About the Publisher
List of Tables
  • Neurosigma Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Neurosigma Inc Pipeline Products by Equipment Type
  • Neurosigma Inc Pipeline Products by Indication
  • Neurosigma Inc Ongoing Clinical Trials by Trial Status
  • Neurosigma Inc, Key Facts
  • Neurosigma Inc, Major Products and Services
  • Neurosigma Inc Number of Pipeline Products by Development Stage
  • Neurosigma Inc Pipeline Products Summary by Development Stage
  • Neurosigma Inc Ongoing Clinical Trials by Trial Status
  • Neurosigma Inc Ongoing Clinical Trials Summary
  • Deep Brain Stimulation System - Cachexia - Product Status
  • Deep Brain Stimulation System - Cachexia - Product Description
  • Deep Brain Stimulation System - Obesity - Product Status
  • Deep Brain Stimulation System - Obesity - Product Description
  • DELTA Stent - Product Status
  • DELTA Stent - Product Description
  • Micropatterned TFN Stent - Product Status
  • Micropatterned TFN Stent - Product Description
  • Monarch eTNS System - ADHD - Product Status
  • Monarch eTNS System - ADHD - Product Description
  • Monarch eTNS System - Depression - Product Status
  • Monarch eTNS System - Depression - Product Description
  • Monarch eTNS System - Depression - External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Depression
  • Monarch eTNS System - Depression - Transcutaneous Vagus Nerve Stimulation for Treating Major Depressive Disorder: A Phase II, Randomized, Double-blind Clinical Trial
  • Monarch eTNS System - Epilepsy - Product Status
  • Monarch eTNS System - Epilepsy - Product Description
  • Monarch eTNS System - Epilepsy - Evaluation of the Monarch eTNS Therapy for Neurological and Neuropsychiatric Disorders in Pediatrics
  • Monarch eTNS System - Epilepsy - External Trigeminal Nerve Stimulation for Epilepsy
  • Monarch eTNS System - Lennox-Gastaut Syndrome - Product Status
  • Monarch eTNS System - Lennox-Gastaut Syndrome - Product Description
  • Monarch eTNS System - Post-Traumatic Stress Disorder - Product Status
  • Monarch eTNS System - Post-Traumatic Stress Disorder - Product Description
  • Monarch eTNS System - Traumatic Brain Injury - Product Status
  • Monarch eTNS System - Traumatic Brain Injury - Product Description
  • Next-Generation eTNS System - Product Status
  • Next-Generation eTNS System - Product Description
  • sTNS System - Epilepsy - Product Status
  • sTNS System - Epilepsy - Product Description
  • Thin Film Nitinol Flow Diverting Stent - Product Status
  • Thin Film Nitinol Flow Diverting Stent - Product Description
Neurosigma Inc, Key Employees
  • Neurosigma Inc, Subsidiaries
  • Glossary
List of Figures
  • Neurosigma Inc Pipeline Products by Equipment Type
  • Neurosigma Inc Pipeline Products by Development Stage
  • Neurosigma Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
  • NeuroMEDx
  • InnovaQuartz LLC
  • CJPS Medical Systems, LLC
Note: Product cover images may vary from those shown
Adroll
adroll